Targeting DNA repair in breast cancer: A clinical and translational update

Cancer Treatment Reviews

Volumn 36, Issue 7, 2010, Pages 557-565

  Amir, Eitan ^a   Seruga, Bostjan ^a   Serrano, Rosario ^a   Ocana, Alberto ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

BRCA1; BRCA2; Breast cancer; PARP inhibitors; Triple negative

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CARBOPLATIN; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; PARP1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; DYSPNEA; EXCISION REPAIR; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MALAISE; MELANOMA; NAUSEA; OVARY CANCER; PANCREAS CANCER; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; PHYSIOLOGY;

BREAST NEOPLASMS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; PTEN PHOSPHOHYDROLASE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 77956169136     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.03.006     Document Type: Review

References (95)

1. Ocana A., Pandiella A. Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res 2008, 14:961-970.
2. Ocana A., Hortobagyi G.N., Esteva F.J. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer 2006, 6:495-504.
3. Hakem R. DNA-damage repair; the good, the bad, and the ugly. Embo J 2008, 27:589-605.
4. Wooster R., Weber B.L. Breast and ovarian cancer. N Engl J Med 2003, 348:2339-2347.
5. Melchor L., Benitez J. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis 2008, 29:1475-1482.
6. Morrow P.K., Hortobagyi G.N. Management of breast cancer in the genome era. Annu Rev Med 2009, 60:153-165.
7. Roukos D.H., Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol 2007, 4:578-590.
8. Garber J.E., Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005, 23:276-292.
9. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
10. Fackenthal J.D., Olopade O.I. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007, 7:937-948.
11. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
12. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
13. Walsh T., Casadei S., Coats K.H., et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379-1388.
14. Turner N., Tutt A., Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005, 5:388-393.
15. Evans D.G., Lalloo F., Cramer A., et al. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009, 12:12.
16. Rennert G., Bisland-Naggan S., Barnett-Griness O., et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007, 357:115-123.
17. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
18. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol Cell 2007, 28:739-745.
19. Kennedy R.D., D'Andrea A.D. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006, 24:3799-3808.
20. van Gent D.C., Hoeijmakers J.H., Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2001, 2:196-206.
21. Cohn M.A., D'Andrea A.D. Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. Mol Cell 2008, 32:306-312.
22. Tutt A., Bertwistle D., Valentine J., et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. Embo J 2001, 20:4704-4716.
23. Moynahan M.E., Chiu J.W., Koller B.H., Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999, 4:511-518.
24. Wang Y., Cortez D., Yazdi P., et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000, 14:927-939.
25. Greenberg R.A., Sobhian B., Pathania S., et al. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 2006, 20:34-46.
26. Pellegrini L., Yu D.S., Lo T., et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002, 420:287-293.
27. Rudkin T.M., Foulkes W.D. BRCA2: breaks, mistakes and failed separations. Trends Mol Med 2005, 11:145-148.
28. Tirkkonen M., Johannsson O., Agnarsson B.A., et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997, 57:1222-1227.
29. Gretarsdottir S., Thorlacius S., Valgardsdottir R., et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998, 58:859-862.
30. Yu V.P., Koehler M., Steinlein C., et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 2000, 14:1400-1406.
31. Bhattacharyya A., Ear U.S., Koller B.H., et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275:23899-23903.
32. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
33. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322.
34. Murphy CG, Singh J, Brunet E et al. Homology-directed repair (HR) is diminished in PTEN-positive breast tumor cells. Cancer Res; 2010 [San Antonio Breast Cancer Symposium Proceedings, Abstract 1120].
35. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
36. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67.
37. Renwick A., Thompson D., Seal S., et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006, 38:873-875.
38. Meijers-Heijboer H., van den Ouweland A., Klijn J., et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55-59.
39. Steffen J., Varon R., Mosor M., et al. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer 2004, 111:67-71.
40. Heikkinen K., Rapakko K., Karppinen S.M., et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006, 27:1593-1599.
41. Seal S., Thompson D., Renwick A., et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241.
42. Erkko H., Xia B., Nikkila J., et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319.
43. Walsh T., King M.C. Ten genes for inherited breast cancer. Cancer Cell 2007, 11:103-105.
44. http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic.
45. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748.
46. Tutt A., Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002, 8:571-576.
47. Balmain A., Gray J., Ponder B. The genetics and genomics of cancer. Nat Genet 2003, 33(Suppl.):238-244.
48. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
49. Catteau A., Harris W.H., Xu C.F., Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999, 18:1957-1965.
50. Esteller M., Silva J.M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92:564-569.
51. Rice J.C., Ozcelik H., Maxeiner P., et al. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000, 21:1761-1765.
52. Narod S.A., Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004, 4:665-676.
53. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180.
54. Lakhani S.R., Van De Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310-2318.
55. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
56. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
57. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
58. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398.
59. Smalley M., Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003, 3:832-844.
60. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344:539-548.
61. Lakhani S.R., O'Hare M.J., Ashworth A. Profiling familial breast cancer. Nat Med 2001, 7:408-410.
62. Jazaeri A.A., Yee C.J., Sotiriou C., et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002, 94:990-1000.
63. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
64. Chew H.K., Doroshow J.H., Frankel P., et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009, 27:2163-2169.
65. Garber JE, Richardson A, Harris LN et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). San Antonio breast cancer symposium (Abstract 3074); 2006.
66. Quinn J.E., Kennedy R.D., Mullan P.B., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63:6221-6228.
67. D'Andrea A.D., Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003, 3:23-34.
68. Audebert M., Salles B., Calsou P. Involvement of poly (ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004, 279:55117-55126.
69. de Murcia J.M., Niedergang C., Trucco C., et al. Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997, 94:7303-7307.
70. Bolderson E., Richard D.J., Zhou B.B., Khanna K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009, 15:6314-6320.
71. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005, 434:913-917.
72. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698.
73. McCabe N., Turner N.C., Lord C.J., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly (ADP-ribose) polymerase inhibition. Cancer Res 2006, 66:8109-8115.
74. Hay T., Jenkins H., Sansom O.J., et al. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly (ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 2005, 65:10145-10148.
75. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
76. Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009;27(18S):CRA501 [Meeting Abstracts].
77. Kopetz S, Mita MM, Mok I et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2008; 26(15_suppl):3577.
78. Mahany JJ, Lewis N, Heath EI et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 2008;26(15 suppl.):3579 [Meeting Abstracts].
79. O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009;27(18S):3 [Meeting Abstracts].
80. O'Shaughnessy J, Osborne C, Pippen J et al. Updated results of a randomized phase ii study demonstrating efficacy and safety of BSI-201, a PARP inhibitor, in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer. Cancer Res; 2010 [San Antonio breast cancer symposium proceedings, Abstract 3122].
81. Plummer R., Jones C., Middleton M., et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-7923.
82. Edwards S.L., Brough R., Lord C.J., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
83. Sakai W., Swisher E.M., Karlan B.Y., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
84. Ocana A, Amir E. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev; 2009.
85. Carracedo A., Baselga J., Pandolfi P.P. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008, 7:3805-3809.
86. Pegram M.D., Konecny G.E., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004, 96:739-749.
87. Li L., Wang H., Yang E.S., et al. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 2008, 68:9141-9146.
88. Seoane S, Montero JC, Pandiella AAO. Effect of dasatinib on the activity of trastuzumab in HER2-overexpressing breast cancer cells. J Clin Oncol 2009;27:15s [suppl; abstr 1084].
89. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609-1615.
90. Rebbeck T.R. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2002, 38(Suppl 6):S15-17.
91. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.
92. Rodon J., Iniesta M.D., Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Invest Drugs 2009, 18:31-43.
93. Ratnam K., Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007, 13:1383-1388.
94. Kummar S., Kinders R., Gutierrez M.E., et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009, 27:2705-2711.
95. Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008, 8:363-369.